Press releases
- Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
- Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
- Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
- Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
More ▼
Key statistics
On Thursday, Relmada Therapeutics Inc (4E2:STU) closed at 2.72, 24.77% above the 52 week low of 2.18 set on Jun 28, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.82 |
---|---|
High | 2.82 |
Low | 2.72 |
Bid | 2.80 |
Offer | 2.92 |
Previous close | 2.90 |
Average volume | 0.00 |
---|---|
Shares outstanding | 30.17m |
Free float | 27.75m |
P/E (TTM) | -- |
Market cap | 93.24m USD |
EPS (TTM) | -3.13 USD |
Data delayed at least 15 minutes, as of May 23 2024.
More ▼